Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
LONDON, December 10, 2013 /PRNewswire/ --
Care Oncology Clinic (COC), an independent, private organisation providing oncology treatments, announces today the launch of its first clinic on London's Harley Street. Delivered by leading oncologists and palliative care doctors, the clinic is the first of its kind, specifically set up to offer a specialised cancer treatment by targeting the energy requirements of cancer cells using existing medicines that are already licensed for this purpose, have an acceptable safety profile and are low cost. Designed for patients for whom the standard oncology treatment regime is not available, viable, tolerable or providing benefit, this is a new option for treating these cancer patients.
Recent research has established that cancer cells function in a completely different way to normal healthy cells. Cancer cells are much more reliant on glucose and fats in the blood (cholesterol) for their energy and for the creation of new cells. A large amount of scientific data has shown that if glucose or cholesterol is reduced, the cancer growth is slowed or halted. Existing and approved medicines used for diabetes and heart patients are capable of reducing glucose and cholesterol while having an acceptable safety profile.
Prof Justin Stebbing, Professor of Cancer Medicine and Oncology, Consultant Oncologist, Imperial College and Consultant at COC, said:
"Care Oncology Clinic is following an approach in treating cancer which uses existing medicines to reduce the availability of resources that cancer cells require for their energy and growth needs. This approach is supported by a large body of scientific data. We believe it is important to collect robust real world data on these approaches and share this with the wider community."
Christina Doherty, CEO of Care Oncology Clinic, added:
"Cancer prevalence rates have been increasing alarmingly and are predicted to rise by 3% a year. Cancer is responsible for more than one in four deaths in the UK, recording over 150,000 deaths in 2011. A number of cancer patients are unable to tolerate existing treatments, and are left with limited, or in some cases, no options. This is the first clinic in the world to offer this treatment in a simple, organised and easily accessible manner. Our objective is to provide affordable treatment to help patients have an acceptable quality of life while dealing with the disease."
1. J Maddams, D Brewster, A Gavin, et al. Cancer Prevalence in the United Kingdom: estimates for 2008. Br J Cancer 2009; 101(3):541-547.
2. Cancer Research UK (2013). Cancer Statistics Report: Cancer Mortality in the UK in 2011 [http://publications.cancerresearchuk.org/downloads/Product/CS_CS_MORTALITY.pdf].
Further information can be found on the website at http://www.careoncologyclinic.com
About Care Oncology Clinics
Care Oncology Clinics is an independent organisation specialising in private cancer treatments.
Our consultants preferentially select medical treatments that have been used by large numbers of people and have demonstrated an acceptable side effect profile, with an aim to help patients try and balance quality of life while fighting the disease. Our consultants also attempt, wherever possible, to choose medicines that are low cost, to provide an affordable treatment option to a wide range of sufferers.
We believe it is important to provide advanced treatment options through collecting and sharing data with the wider community.
Oncologists and Consultants at the Clinic include:
Professor Justin Stebbing, MD MA FRCP FRCPath PhD
Professor Angus Dalgleish, MD FRACP FRCP FRCPath FMedSci
Dr David Feuer, BSc BM FRCP
For more information please contact:
Gregory Stoloff / Christina Doherty - Tel +44(0)207-153-6601
Mary Clark / Hollie Vile / Supriya Mathur - Tel +44(0)20-3440-5654
©2012 PR Newswire. All Rights Reserved.